Browsing by Yonsei Author : Roh, Jae Kyung

eperson profile image
Name:
Roh, Jae Kyung [노재경]
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 177

This table browses all dspace content
Issue DateTitleJournal Title
2017Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial INTERNATIONAL JOURNAL OF CANCER
2017Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer ONCOLOGY LETTERS
2016p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer CANCER RESEARCH AND TREATMENT
2015A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal CancerINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
2015Leiomyosarcoma: investigation of prognostic factors for risk-stratification modelINTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
2015Novel methods for clinical risk stratification in patients with colorectal liver metastases CANCER RESEARCH AND TREATMENT
2015Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependencyANNALS OF SURGICAL ONCOLOGY
2015Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children CANCER RESEARCH AND TREATMENT
2014Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center StudyONCOLOGY
2014Japanese Cancer Association Meeting UICC International Session - What is Cost-effectiveness in Cancer Treatment? ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
2014Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation studyJOURNAL OF CLINICAL PATHOLOGY
2013Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort StudyANNALS OF SURGICAL ONCOLOGY
2013Changing treatment patterns in elderly patients with resectable colon cancerASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2013Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells.ANTICANCER RESEARCH
2013Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors SUPPORTIVE CARE IN CANCER
2013Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic ToolANNALS OF SURGICAL ONCOLOGY
2013Union for International Cancer Control International Session: Healthcare Economics: The significance of the UN summit non-communicable diseases political declaration in AsiaCANCER SCIENCE
2013Estimating the Adjuvant Chemotherapy Effect in Elderly Stage II and III Colon Cancer Patients in an Observational StudyJOURNAL OF SURGICAL ONCOLOGY
2013Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agentINVESTIGATIONAL NEW DRUGS
2012Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancerSURGICAL ONCOLOGY-OXFORD
2012Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research GroupJOURNAL OF CLINICAL ONCOLOGY
2012A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapyINVESTIGATIONAL NEW DRUGS
2012A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapyINVESTIGATIONAL NEW DRUGS
2012VIPoma that arose from the rectum in a 65-year-old male patientINTERNATIONAL JOURNAL OF COLORECTAL DISEASE
2012Methylation status of lamin A/C in gastric cancer cell linesHEPATO-GASTROENTEROLOGY
2012Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis CANCER RESEARCH AND TREATMENT
2012Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience BMC CANCER
2012Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometryANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY
2011Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasisONCOLOGY
2011Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
2011Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremityONCOLOGY
2011Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY
2011Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancerINVESTIGATIONAL NEW DRUGS
2011Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancerANTI-CANCER DRUGS
2011A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy CANCER
2011Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis.ONCOLOGY REPORTS
2011Brain metastases from colorectal carcinoma: prognostic factors and outcomeJOURNAL OF NEURO-ONCOLOGY
2010Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites CANCER RESEARCH AND TREATMENT
2010The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-upANNALS OF SURGICAL ONCOLOGY
2010Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistanceCANCER CHEMOTHERAPY AND PHARMACOLOGY
2010Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progressionCANCER SCIENCE
2010A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancerINVESTIGATIONAL NEW DRUGS
2010Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial designCANCER CHEMOTHERAPY AND PHARMACOLOGY
2010Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticatorsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2010Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancerRADIOTHERAPY AND ONCOLOGY
2010A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
2010Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer JAPANESE JOURNAL OF CLINICAL ONCOLOGY
2010Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patientsCANCER LETTERS
2009A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance statusONCOLOGY
2009Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.LANCET

Browse

Links